| PTEN in colorectal cancer: shedding light on its role as predictor and target L Salvatore, MA Calegari, F Loupakis, M Fassan, B Di Stefano, M Bensi, ... Cancers 11 (11), 1765, 2019 | 73 | 2019 |
| Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine–DNA methyltransferase–silenced metastatic … F Morano, A Raimondi, F Pagani, S Lonardi, L Salvatore, C Cremolini, ... Journal of Clinical Oncology 40 (14), 1562, 2022 | 62 | 2022 |
| A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’study F Loupakis, R Intini, C Cremolini, A Orlandi, A Sartore-Bianchi, ... European Journal of Cancer 118, 121-130, 2019 | 57 | 2019 |
| A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation MA Calegari, A Inno, S Monterisi, A Orlandi, D Santini, M Basso, ... British Journal of Cancer 116 (10), 1279-1286, 2017 | 48 | 2017 |
| Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer IV Zurlo, M Schino, A Strippoli, MA Calegari, A Cocomazzi, A Cassano, ... Cancer Immunology, Immunotherapy 71 (1), 45-55, 2022 | 47 | 2022 |
| KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients M Basso, A Strippoli, A Orlandi, M Martini, MA Calegari, G Schinzari, ... British journal of cancer 108 (1), 115-120, 2013 | 38 | 2013 |
| Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report A Orlandi, R Fasciani, A Cassano, A Agresta, MA Calegari, A Caporossi, ... BMC cancer 15, 1-3, 2015 | 34 | 2015 |
| Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature P Sollena, M Mannino, F Tassone, MA Calegari, E D’Argento, K Peris Drugs in context 8, 2019 | 24 | 2019 |
| Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse A Orlandi, MA Calegari, M Martini, A Cocomazzi, C Bagalà, G Indellicati, ... Clinical and Translational Oncology 18, 988-995, 2016 | 24 | 2016 |
| ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line: in vitro veritas A Orlandi, M Di Salvatore, C Bagalà, M Basso, A Strippoli, F Plastino, ... Journal of Cancer 6 (1), 70, 2015 | 23 | 2015 |
| Evaluation of second-line anti-VEGF after first-line Anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: the Multicenter “SLAVE” Study A Parisi, A Cortellini, K Cannita, O Venditti, F Camarda, MA Calegari, ... Cancers 12 (5), 1259, 2020 | 19 | 2020 |
| BRAF in metastatic colorectal cancer: the future starts now A Orlandi, MA Calegari, A Inno, R Berenato, M Caporale, M Niger, I Bossi, ... Pharmacogenomics 16 (18), 2069-2081, 2015 | 19 | 2015 |
| The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases M Basso, S Corallo, MA Calegari, IV Zurlo, F Ardito, M Vellone, ... Scientific Reports 10 (1), 10871, 2020 | 15 | 2020 |
| Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase S Schwartz, C Szeto, Y Tian, F Cecchi, S Corallo, MA Calegari, ... European Journal of Cancer 107, 164-174, 2019 | 11 | 2019 |
| Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era? IV Zurlo, M Basso, A Strippoli, MA Calegari, A Orlandi, A Cassano, ... Cancers 12 (7), 1749, 2020 | 10 | 2020 |
| LBA22 phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic … C Pinto, A Orlandi, N Normanno, E Maiello, MA Calegari, L Antonuzzo, ... Annals of Oncology 33, S1390, 2022 | 9 | 2022 |
| Discordance of KRAS mutational status between primary tumors and liver metastases in colorectal cancer: Impact on long-term survival following radical resection F Ardito, F Razionale, L Salvatore, T Cenci, M Vellone, M Basso, ... Cancers 13 (9), 2148, 2021 | 9 | 2021 |
| Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? R Moretto, A Elliott, D Rossini, R Intini, V Conca, F Pietrantonio, ... British Journal of Cancer 127 (5), 957-967, 2022 | 8 | 2022 |
| FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis. MA Calegari, IV Zurlo, B Di Stefano, F Camarda, C Di Dio, G Garufi, ... Journal of Clinical Oncology 37 (4_suppl), 669-669, 2019 | 6 | 2019 |
| Clinical, pathological and prognostic features of rare BRAF mutations in metastatic colorectal cancer (mCRC): a Bi-institutional retrospective analysis (REBUS study) MA Calegari, L Salvatore, B Di Stefano, M Basso, A Orlandi, A Boccaccino, ... Cancers 13 (9), 2098, 2021 | 5 | 2021 |
